No Patient Left Behind

Nearly a million Americans are living with multiple sclerosis. Meet some of the biotech innovators racing to develop breakthrough treatments for patients and their families still waiting for a cure. Together, we can create a future without MS.

🔗 nopatientleftbehind.org/our-quest-to-b…

Autoimmune diseases affect 45M+ Americans. This #AutoimmuneAwarenessMonth, we recognize everyone working to improve the lives of people impacted by autoimmune disease. Progress is collective and personal. 📽️ Watch below:

Innovation is fragile. Yesterday, our ED Priscilla talked with our fellows on the fix: lead with affordability, fix insurance, call out rent-seeking, and tell real stories of pre-revenue biotech risk. nopatientleftbehind.org/fellowship #NPLBFellowship #Biotech

🔗 nopatientleftbehind.org/our-quest-to-c…

Today is #WorldCancerDay. Today we recognize the patients and families, the progress already made against cancer, and the urgent need for continued innovation. Progress takes all of us. 📽️  Watch our reposted Community Quest video below:

From MS at Johns Hopkins to Healthcare Investment Banking, Conor Ratigan explains why the NPLB Biotech Fellowship is a game-changer for bridging academia and industry. Learn the Biotech Social Contract & master the ecosystem. ⏳Today is the day! Apply by midnight 👇 nopatientleftbehind.org/fellowship #NPLBFellowship #Biotech #Innovation

Vision loss from glaucoma is often gradual, but its impact is life-changing. This #GlaucomaAwarenessMonth, we recognize the patients, innovators, and supporters working toward a future where fewer people lose their sight. 🎥 Meet some of them here: nopatientleftbehind.org/the-quest-to-t…

Learn what every future biotech leader should know but isn’t taught in school. 🏫 Even top academic programs leave key questions unanswered. That’s where the NPLB Biotech Fellowship comes in. @PeterKolchinsky explains the program here: youtu.be/YE4uTm_V68E?fe… ⏳Apply soon! #NPLBFellowship #BiotechSocialContract #AffordableInnovation #Biotech

ICYMI: Great @Freakonomics Radio interview w/@MartyMakary on modernizing the @US_FDA. Cutting outdated animal tests, using real-world data, and shrinking review times from years to weeks—without sacrificing safety. More competition = more cures, more patient access, more generics + lower costs. 🎧 freakonomics.com/podcast/can-ma… #biotech #FDA #innovation #patients

🔬 Want to understand how drugs are developed and made affordable? Join NPLB Biotech Fellows → live sessions, real-world projects, and a global network spanning every top 50+ U.S. university. 👉 Apply now to join us this spring: nopatientleftbehind.org/fellowship #NPLBFellowship #BiotechSocialContract #AffordableInnovation #Biotech

💡From Price Controls to Breakthrough Cures Ayse Tezcan, MPH, PhD Tezcan, an entrepreneur and epidemiologist focused on affordable cancer care, called the NPLB Biotech Fellowship “a truly transformational experience.” 🧠 Ready to transform your understanding of biotech? 🕒 Apply this January to join us this spring: lnkd.in/eR44KBnB #NPLBFellowship #BiotechSocialContract #AffordableInnovation #Biotech #Fellowship #Healthcare

Our executive director, Peter Rubin, sat down with Jessica D’Amico from @fwpharma to discuss the risks of “Most-Favored Nation" pricing models, including how there's no guarantee that these new savings will be passed on to patients. 🔗 Read their full conversation here: firstwordpharma.com/story/7046682

We cure diseases — but in MA, we haven’t cured misconceptions about biotech. The MA Paradox is not a data problem. It’s a storytelling problem. Learn more: nopatientleftbehind.org/ma-paradox

Would the NFL have fans if they played their games in private and just promoted the winner? Of course not. Biopharma’s biggest communication failure: It only markets its wins. For people to root for biotech innovation, we have to invite them in. 🔗 bit.ly/44GR49Y

@PeterKolchinsky Check out the slide deck here: nopatientleftbehind.docsend.com/view/eij22esj3…

We analyzed impact of CMS's "experimental" GLOBE/GUARD policies to cap US prices at what other countries pay (answer: backfire). Note: doesn't lower what patients pay... that's a function what insurance gets away with charging sick people out of pocket. rapport.racap.com/all-stories/gl…

Michigan protects autos. Iowa protects farmers. California protects entertainment. So why doesn’t Massachusetts fight for biotech — the engine of its economy and key source for cures? 👉 Learn more about the MA Paradox: nopatientleftbehind.org/ma-paradox

November is National Caregivers Month. 💜 Caregivers carry personal + financial burdens that are often overlooked when new meds are valued. Ignoring caregiver burden undervalues innovation & can limit options to return time + stability. 🔗 Learn more: nopatientleftbehind.org/value-of-medic…

The record-setting government shutdown was just the latest blow to the U.S. biopharma industry. When science funding becomes a casualty of political gridlock, we lose valuable talent, erode public trust and jeopardize our position as a global leader in innovation. #opinion #biopharma #biospace hubs.li/Q03VXFMX0

Tomorrow we give thanks. Today we thank the innovators working to keep us around the table for years to come. Our #CommunityQuest series shows one truth: breakthroughs don’t happen alone. 🎥 Watch: nopatientleftbehind.org/community-ques… & Happy Thanksgiving from NPLB.

300+ investors, innovators, physicians & patients unite w/ NPLB to call for a modern, science-first FDA. We applaud Dr. Pazdur’s appointment & reaffirm that FDA’s strength lies in its expert workforce & clear, consistent pathways to developing meds. 🔗 bit.ly/4iwCszO